ShareValue.ai

ShareValue scores for ASTRAZEN.NSE: Valuation 35, Quality 57, Growth 85, Health 55.

ASTRAZEN.NSE
NSE

AstraZeneca Pharma India Limited

₹8,391.00(-0.60%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-4% to 11%
Valuation
35
Overvalued
Price vs Value
Quality
57
Moderate
Business Strength
Growth
85
Strong
Revenue & Earnings
Health
55
Moderate
Financial Stability
Momentum
41
Neutral
Price Trend

Company Details

About

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026